New Market Report: United Arab Emirates Pharmaceuticals & Healthcare Report Q1 2015

The UAE will retain its position as an attractive market for innovative drugmakers due to the population's preference for patented drugs, high per capita expenditure on pharmaceuticals and continued government investment in the healthcare sector. Pharmaceutical companies with product portfolios geared towards the treatment of chronic diseases will be provided with a rapidly expanding patient base. However, we highlight that medicine price cuts throughout the Gulf Cooperation Council states will become more frequent, dampen ing profit margins for innovative drugs.

Full Report Details at
- http://www.fastmr.com/prod/944665_united_arab_emirates_pharmaceuticals_healthcare.aspx?afid=301

Headline Expenditure Projections

* Pharmaceuticals: AED8.14bn (USD2.22bn) in 2013 to AED8.30bn (USD2.26bn) in 2014; +2.0% in local currency and US dollar terms. Forecast adjusted from last quarter to better suit current market conditions.
* Healthcare: AED42.68bn (USD11.62bn) in 2013 to AED44.93bn (USD12.24bn) in 2014; +5.3% in local currency terms and +5.4% US dollar terms. Forecast revised downward from last quarter to better suit current market conditions.

Risk/Reward Index

In our Q414 Pharmaceutical Risk/Reward Index (RRI), the UAE scores 58.6 and is ranked second out of a total of 31 markets in our Middle East and Africa regional matrix.

Key Trends & Developments

November 2014

* The Dubai Health Authority (DHA) imposed a price cap on the cost of health services in Dubai, which is expected to bring a sustainable synergy between healthcare providers and patients' interests. The DHA has set a 4.2% limit for 2015 effective from January 1, to ensure that healthcare providers do not exploit the free market principles. The cap is not a price-fixing measure but a regulatory mechanism aimed to balance supply and demand, according to the DHA. Under the new policy, the DHA will investigate the validity and purpose of each price increase application by a healthcare provider on a single service-by-service basis, as opposed to a blanket hike. The DHA will also impose severe penalties on violators...

The United Arab Emirates Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's United Arab Emirates Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the United Arab Emirates pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for United Arab Emirates, to test other views - a key input for successful budgeting and strategic business planning in the Emirati pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- United Kingdom Pharmaceuticals & Healthcare Report Q1 2015
- United States Pharmaceuticals & Healthcare Report Q1 2015
- Germany Pharmaceuticals & Healthcare Report Q1 2015
- Jordan Pharmaceuticals & Healthcare Report Q1 2015
- Egypt Pharmaceuticals & Healthcare Report Q1 2015